Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms NeoTRIPaPDL1
- 14 Jul 2016 Last checked against ClinicalTrials.gov record.
- 12 Jul 2016 Status changed from not yet recruiting to recruiting.
- 20 Apr 2016 Planned End Date changed from 1 Jun 2022 to 1 Oct 2022.